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CTLA-4 as a genetic determinant in autoimmune Addison’s
disease
ASB Wolff1,10, AL Mitchell2,10, HJ Cordell2, A Short3, B Skinningsrud4,5, W Ollier3, K Badenhoop6, G Meyer6, A Falorni7, O Kampe8,
D Undlien4,5, SHS Pearce2 and ES Husebye1,9
In common with several other autoimmune diseases, autoimmune Addison’s disease (AAD) is thought to be caused by a
combination of deleterious susceptibility polymorphisms in several genes, together with undeﬁned environmental factors and
stochastic events. To date, the strongest genomic association with AAD has been with alleles at the HLA locus, DR3–DQ2 and DR4.
The contribution of other genetic variants has been inconsistent. We have studied the association of 16 single-nucleotide
polymorphisms (SNPs) within the CD28–CTLA-4–ICOS genomic locus, in a cohort comprising 691 AAD patients of Norwegian and
UK origin with matched controls. We have also performed a meta-analysis including 1002 patients from European countries.
The G-allele of SNP rs231775 in CTLA-4 is associated with AAD in Norwegian patients (odds ratio (OR) = 1.35 (conﬁdence interval
(CI) 1.10–1.66), P= 0.004), but not in UK patients. The same allele is associated with AAD in the total European population (OR = 1.37
(CI 1.13–1.66), P= 0.002). A three-marker haplotype, comprising PROMOTER_1661, rs231726 and rs1896286 was found to be
associated with AAD in the Norwegian cohort only (OR 2.43 (CI 1.68–3.51), P= 0.00013). This study points to the CTLA-4 gene as
a susceptibility locus for the development of AAD, and reﬁnes its mapping within the wider genomic locus.
Genes and Immunity (2015) 16, 430–436; doi:10.1038/gene.2015.27; published online 23 July 2015
INTRODUCTION
Primary adrenal insufﬁciency (Addison’s disease, AD) is most often
caused by autoimmune destruction of the adrenal cortices,
resulting in insufﬁcient production of the steroid hormones,
cortisol and aldosterone. Autoimmune diseases, including auto-
immune AD (AAD), cluster in families and are believed to share
some common etiological factors. The underlying mechanisms
resulting in AAD are still obscure, but a contribution from genetic
variants is clear.1,2 The strongest genomic associations have been
reported with the human leukocyte antigen (HLA) haplotypes
DR3–DQ2 and DR4 (subtype DRB1*0404)-DQ8) in several
populations.3–6 Other associations include variants in genes
involved in T-cell signalling and activation, especially the 1858T
allele (rs2476601) of the tyrosine-protein phosphatase nonreceptor
type 22 (PTPN22) gene.7 The product of this gene, lymphoid
tyrosine phosphatase (LYP), acts as an essential mediator of T-cell
receptor (TCR) signalling by controlling phosphorylation/depho-
sphorylation of key signalling pathway kinases.8 Polymorphisms in
STAT4, linked to CD4+ cell fate and GATA3, involved in CD8+ cell
homeostasis, have also been found to confer susceptibility to
AAD.9 In addition, other genes that encode cell-surface receptors
that regulate activation responses in T lymphocytes, for example,
CD274 (programmed death ligand 1)10 and cytotoxic T-lympho-
cyte antigen-4, CTLA-4 (CD152)11–13 have also been linked to AAD
susceptibility. CTLA-4, which is encoded by a gene located on
chromosome 2q33, competes with the costimulator CD28 for
binding to B7 on antigen-presenting cells, and downregulates
T-cell responses to antigen-presentation/T-cell receptor engage-
ment. Several studies have implicated CTLA-4 single-nucleotide
polymorphisms (SNPs) in autoimmune diseases, including AAD.
Recently, Schubert et al.14 described heterozygous mutations in
CTLA-4 that resulted in a dominantly inherited complex immune
dysregulation syndrome due to disruption of immune cell balance.
Importantly, slightly different patterns of genetic association have
been seen in different autoimmune conditions, including with
alleles of the ﬂanking CD28 and inducible costimulator (ICOS)
genes, suggesting that different variants within this extended
locus could predispose to different autoimmune conditions.15
Etiological variants at the CTLA-4 locus might result in either a
deﬁcient or an overexuberant CTLA-4 response relative to CD28,
which interferes with immune homeostasis. Furthermore, CTLA-4
is constitutively expressed on regulatory T cells (Tregs). It has been
suggested that this is one of the crucial, innate protective
mechanisms against infectious agents and prevents the expansion
of pathogenic T-cell clones.16 Blockade of CTLA-4 activity has also
been shown to abrogate Treg function in several experimental
situations, perhaps promoting an environment permissive to
autoreactivity.17,18
The association between CTLA-4 gene variants and AAD has
previously been reported in some but not all studies of different
European populations.3,11–13,19,20–22 Of particular interest is the
common nonsynonymous CTLA-4 polymorphism rs231775, also
called exon 1 +49A→G (Ala17Thr). Although this SNP was found
1Department of Clinical Science, University of Bergen, Bergen, Norway; 2Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK; 3Centre for Integrated
Genomic Medical Research, Institute of Population Health, Manchester University, Manchester, UK; 4Institute of Medical Genetics, University of Oslo, Oslo, Norway; 5Department
of Medical Genetics, Oslo University Hospital, Oslo, Norway; 6Department of Endocrinology and Diabetes, Internal Medicine 1, Johann-Wolfgang-Goethe-University´s Hospital,
Frankfurt, Germany; 7Department of Medicine, University of Perugia, Perugia, Italy; 8Department of Medicine, Solna, Karolinska University Hospital, Karolinska Institutet,
Stockholm, Sweden and 9Department of Medicine, Haukeland University Hospital, Bergen, Norway. Correspondence: Dr ASB Wolff, Department of Clinical Science, University of
Bergen, Laboratory Building, 8th Floor, Bergen 5021, Norway.
E-mail: Anette.boe@k2.uib.no
10These authors contributed equally to this work.
Received 4 May 2015; revised 11 June 2015; accepted 16 June 2015; published online 23 July 2015
Genes and Immunity (2015) 16, 430–436
© 2015 Macmillan Publishers Limited All rights reserved 1466-4879/15
www.nature.com/gene
to be associated with AAD in Italy,3 this ﬁnding was not replicated
in studies from Germany,21 Spain22 or Norway.20 In the UK
population, results have been conﬂicting with one study ﬁnding
an association12 and another failing to replicate this ﬁnding.20
Other polymorphisms in CTLA-4 have shown similar inconclusive
patterns of association.3,11,20
The main limitation of all the previous studies of CTLA-4 gene
variation in AAD has been insufﬁcient statistical power due to the
small patient cohorts studied, owing to the rarity of AAD. To
overcome this, we have now collected DNA from 691 AAD
patients from Norway and the UK and explored several
polymorphisms in the CD28-CTLA-4-ICOS region within these
cohorts using a tag-SNP approach. We also performed a meta-
analysis of studies that have examined the CTLA-4 rs231775 variant
in European populations.
RESULTS
CD28 and CTLA-4 are associated with AAD in the Norwegian
patient cohort, but not in UK AAD patients
Sixteen SNPs were analysed in the extended CTLA-4 gene locus in
the UK and Norwegian AAD cohorts and compared with the allele
and genotype frequencies of healthy controls of the same ethnic
origins (Allele distribution with re-labelling #1–16 shown in
Figure 1). Two SNPs did not meet the call rate criteria (that is,
combined call rate495%) from the UK cohort (rs11571308 (#6)
and rs231730 (#12)) and from the Norwegian cohort (rs1181389
(#3) and rs5742909 (#7)). These were excluded from further
analysis.
Genotypes and allele frequencies of one SNP, rs3181096 (#2),
located close to the start of the CD28 gene (Figure 1), were
associated with AAD in the combined cohort (all UK and
Norwegian patients), and in the Norwegian cohort alone
(Table 1). When we further separated the Norwegian patients
into isolated AAD (iAAD) or APS II, or those with 21-hydroxylase
(21-OH) antibodies, all subgroups remained signiﬁcantly
associated. However, there was no association in the UK patients
when analysed alone (Table 1).
Five SNPs, all located within, or very close to, CTLA-4, were
associated with AAD in the Norwegian cohort: rs231775 (#9),
rs231726 (10), rs231727 (#11), rs2882973 (#13) and rs3116505 (#14)
(Table 1). In the combined cohort, the G-allele of rs231775 (#1),
was associated. This association was also seen in both the
Norwegian and UK APS II subgroups, and in the 21-OH positive
Norwegian subgroup. At rs231726 (#10), rs231727 (#11), rs2882973
(#13) and rs3116505 (#14), the association was speciﬁc for
Norwegian APS II patients, rather than for iAAD. SNPs in ICOS
were not associated with AAD in the either cohort.
The haplotype ‘PROMOTER_1661, rs231726 and rs1896286’ is
associated with AAD in the Norwegian cohort
A three-marker haplotype, comprising PROMOTER_1661 (#7),
rs231726 (#10) and rs1896286 (#16) was found to be associated
with AAD in the Norwegian cohort only. The major haplotype
(A–C–T) was found with a frequency of 34.9% in the Norwegian
control cohort. Association was found with the A–T–T haplotype,
found in 25.2% of Norwegian cases compared with only 15.8% of
Norwegian controls (odds ratio (OR) 2.43 (conﬁdence interval (CI)
1.68–3.51)). The stepwise inclusion of additional markers did not
improve the model, and when the data set was conditioned for
SNPs within the CTLA-4 gene, markers in the CD28 gene were not
found to be exerting an independent effect.
CTLA-4 (rs231775) is strongly associated with AAD in the European
population; a meta-analysis from studies including patients from
Norway, UK, Germany, Spain and Italy
The SNP rs231775 (#9) has previously been studied in other AAD
populations and found to be associated with disease. We conﬁrm
a strong correlation between this SNP and development of AAD in
a random effects meta-analysis comprising 1002 patients and
1614 controls (Table 2), of which ~ 60% came from our current
study. Overall, the OR for the association of the G-allele with AAD
was 1.37 (CI 1.13–1.66), P= 0.002.
DISCUSSION
Variants in the CTLA-4 gene have been found to have a role in
susceptibility to several autoimmune diseases in different popula-
tions, including autoimmune endocrinopathies such as Graves’
disease, autoimmune hypothyroidism and type 1 diabetes,
(reviewed by Kavvoura et al.23, Kristiansen et al.24 and Ueda
et al.25). The signiﬁcance of CTLA-4 polymorphisms in AAD
susceptibility remains controversial, as different studies have
reported conﬂicting ﬁndings.3,11–13,19,20–22 We have studied the
contribution of SNPs in and around the CTLA-4 gene to AAD
development in a large population comprising almost 700
patients from Norway and the UK. We conclude that several of
the SNPs located in close proximity to the CD28 gene and to CTLA-
4, including the G-allele of the common polymorphism rs231775
(#9), were signiﬁcantly associated with AAD in the Norwegian
population, but not in the UK patient cohort. This ﬁnding is in
agreement with those of a previous study by Vaidya from 2000
which included 90 patients,12 but conﬂicts with the ﬁndings
reported by Blomhoff from 2004 on 134 UK patients.20 However,
these previous studies were conducted on much smaller cohorts,
and hence are signiﬁcantly less powerful than the current study.
Other studies have indicated that CTLA-4, and not the neighbour-
ing genes encoding CD28 and ICOS, are involved in susceptibility
to autoimmune diseases.25–27 This study shows an association
62 kbI30 kb
CTLA-4 ICOS
R
s3
18
10
96
 * 
(2
)
R
s1
18
13
89
 in
tr
on
 (3
)
R
s1
18
13
88
 in
tr
on
 (4
)
R
s3
11
65
07
  *
* (
5)
Pr
om
ot
er
_1
66
1*
 (7
)
R
s5
74
29
09
* (
8)
R
s2
31
77
5 
Ex
on
 1
 (9
)
R
s2
31
72
6 
**
 (1
0)
R
s2
31
72
7 
**
 (1
1)
R
s2
31
73
0 
**
 (1
2)
R
s2
88
29
73
 * 
(1
3)
R
s3
11
65
05
* (
14
)
R
s1
01
83
08
7 
3*
U
TR
 (1
5)
R
s1
89
62
86
**
 (1
6)
R
s1
15
71
30
8 
(6
)
D
IL
10
7*
 (1
)
CD28
Figure 1. An overview of the SNPs that were analysed in this study. For simplicity, the SNPs are also labelled 1–16. *5′ near gene; **3′
near gene.
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Table 1. The distribution of alleles of 16 SNPs in the extended CTLA-4 gene locus encompassing CD28, CTLA-4 and ICOS in the Norwegian and UK
patients and controls cohorts
DIL107 AAD G AAD T Ctrls G Ctrls T Call rate OR Z P Q hetero P hetero Weight iAAD APS II 21-OH+ N
UK 489 129 500 150 0.985 1.14 0.95 0.344 48.24 P= 0.52 P= 0.39
Norway 575 177 591 155 0.98 0.85 − 1.29 0.199 51.76 P= 0.99 P= 0.57 P= 0.22
Meta random 0.98 − 0.14 0.885 2.45 0.12 P= 0.65 P= 0.06
rs3181096 AAD C AAD T Ctrls C Ctrls T Call rate OR Z P Q hetero P hetero Weight iAAD APS II 21-OH+ N
UK 412 198 412 218 0.965 1.1 0.8 0.424 45.6 P= 0.31 P= 0.73
Norway 504 236 464 284 0.975 1.31 2.46 0.014 54.4 P= 0.054 P=0.041 P=0.006
Meta random 1.21 2.22 0.027 1.12 0.29 P=0.03 P= 0.13
rs1181389 AAD T AAD C Ctrl T Ctrl C Call rate OR Z P Q hetero P hetero Weight iAAD APS II 21-OH+ N
UK 476 104 583 102 0.95 0.8 − 1.46 0.145 45.98 P= 0.43 P= 0.46
rs1181388 AAD G AAD A Ctrl G Ctrl A Call rate OR Z P Q hetero P hetero Weight iAAD APS II 21-OH+ N
UK 515 81 551 105 0.97 1.21 1.2 0.231 47.55 P= 0.29 P= 0.15
Norway 636 114 631 103 0.975 0.91 − 0.64 0.525 52.45 P= 0.50 P= 0.69 P= 0.52
Meta random 1.04 0.3 0.767 1.72 0.19 P= 0.84 P= 0.77
rs3116507 AAD A AAD G Ctrl A Ctrl G Call rate OR Z P Q hetero P hetero Weight iAAD APS II 21-OH+ N
UK 475 141 496 144 0.98 0.98 − 0.16 0.869 45.38 0.40 P= 0.57
Norway 565 183 570 164 0.975 0.89 − 0.96 0.335 54.62 0.54 P= 0.35 P= 0.21
Meta random 0.93 − 0.82 0.41 0.28 0.6 P= 0.92 P= 0.18
rs11571308 AAD C AAD T Ctrl C Ctrl T Call rate OR Z P Q hetero P hetero Weight iAAD APS II 21-OH+ N
Norway 646 92 651 87 0.97 0.94 − 0.4 0.69 59.04 P= 0.47 P= 1.0 P= 0.90
rs5742909 AAD C AAD T Ctrl C Ctrl T Call rate OR Z P Q hetero P hetero Weight iAAD APS II 21-OH+ N
UK 560 44 588 36 0.955 0.78 − 1.07 0.283 37.72 P= 0.57 P= 0.11
Promoter_1661 AAD A AAD G Ctrl A Ctrl G Call rate OR Z P Q hetero P hetero Weight iAAD APS II 21-OH+ N
UK 486 94 556 94 0.956 0.87 − 0.85 0.396 42.94 1.00 P= 0.92
Norway 611 135 598 122 0.965 0.92 − 0.58 0.562 57.06 0.53 P= 0.73 P= 0.61
Meta random 0.9 − 0.99 0.32 0.07 0.79 P= 0.63 P= 0.27
rs231775 AAD A AAD G Ctrl A Ctrl G Call rate OR Z P Q hetero P hetero Weight iAAD APS II 21-OH+ N
UK 361 257 400 260 0.995 0.91 − 0.8 0.425 47.52 0.19 P=0.013
Norway 382 370 437 313 0.985 0.74 − 2.9 0.004 52.48 0.10 P=0.003 P=0.003
Meta random 0.82 − 1.91 0.055 1.87 0.17 P=0.04 P= 0.27
rs231726 AAD C AAD T Ctrl C Ctrl T Call rate OR Z P Q hetero P hetero Weight iAAD APS II 21-OH+ N
UK 387 211 410 222 0.955 0.99 − 0.06 0.954 48.49 P= 0.67 P=0.008
Norway 411 325 467 269 0.965 0.73 − 2.97 0.003 51.51 P= 0.10 P=0.002 P=0.002
Meta random 0.85 − 1.08 0.282 3.75 0.05 P= 0.16 P= 0.40
rs231727 AAD G AAD A Ctrl G Ctrl A Call rate OR Z P Q hetero P hetero Weight iAAD APS II 21-OH+ N
UK 381 207 433 225 0.965 0.96 − 0.37 0.709 47.47 P= 0.41 P=0.023
Norway 420 328 457 269 0.97 0.75 − 2.66 0.008 52.53 P= 0.09 P=0.007 P=0.007
Meta Random 0.84 − 1.43 0.154 2.22 0.14 P= 0.10 P= 0.36
rs231730 AAD T AAD A Ctrl T Ctrl A Call rate OR Z P Q hetero P hetero Weight iAAD APS II 21-OH+ N
Norway 586 150 579 141 0.955 0.95 − 0.38 0.704 56.97 P= 0.35 P= 0.85 P= 0.85
rs2882973 AAD T AAD C Ctrl T Ctrl C Call rate OR Z P Q hetero P hetero Weight iAAD APS II 21-OH+ N
UK 401 215 431 225 0.985 0.97 − 0.23 0.821 46.53 P= 0.56 P= 0.13
Norway 453 301 490 262 0.99 0.8 − 2.04 0.042 53.47 P= 0.20 P=0.048 P=0.02
Meta random 0.88 − 1.35 0.176 1.44 0.23 P= 0.18 P= 0.37
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with CTLA-4 and AAD but no independent association between
CD28 or ICOS and AAD, the latter of which had been previously
suggested. We further show that for some of the SNPs in CTLA-4,
the association with AAD is only true when AAD presents in
combination with type 1 diabetes or thyroid disease (that is, APS II).
It is possible that the positive association with these variants is
due to both or one of these accompanying endocrine auto-
immune conditions rather than to AAD in particular.
Haplotype analysis revealed that the haplotype PROMO-
TER_1661(A)-rs231726 (T)-rs1896286 (T) (#7#10#16) was signiﬁ-
cantly associated with AAD in the Norwegian cohort,
strengthening the hypothesis of a role for CTLA-4 in AAD
susceptibility. Markers in the CD28 gene were not found to exert
an independent effect; hence, we speculate that the CD28
association with AAD is the result of linkage disequilibrium
between CTLA-4 and CD28 alleles. A recent study suggested that
the conﬂicting results of CD28, CTLA-4 and ICOS candidate gene
association studies is due to population stratiﬁcation. That is, the
presence of systematic differences in allele frequencies between
covert subpopulations within a population.28 This phenomenon is
likely to explain the differing results in the UK and Norwegian
cohorts studied here, even though the formal tests for genetic
heterogeneity between the two populations were not overtly
discrepant. It is also plausible that the real percentage of patients
with Addison’s disease in whom the disease is in fact caused by
pathological autoimmunity differ. However, we have tested the
Norwegian cohort in this study and in a pilot subgroup of British
AAD patients for autoantibodies against 21-OH, a positive marker
for an ongoing autoimmune condition against the adrenals, and
found similar results (data not shown). Deviations of results in
different populations have also been reported for CTLA-4
associations with, for example, type 1 diabetes and autoimmune
thyroid diseases (reviewed in Hou et al.29 and Wang et al.30).
Notably, however, when the data indicate an association, it is most
often with the same allele (for example, the G-allele concerning
rs231775). As most autoimmune diseases are thought to be
caused by a combination of unfavourable genetic factors (in
addition to environmental triggers), a possibility exist that
different genes have different impact on the association risk
based on underlying genetics speciﬁc for each populations and
ethnic groups. Hence, CTLA polymorphisms might be important
Table 1. (Continued )
rs3116505 AAD C AAD T Ctrl C Ctrl T Call rate OR Z P Q hetero P hetero Weight iAAD APS II 21-OH+ N
UK 395 211 411 217 0.96 0.99 -0.1 0.922 46.71 P= 0.68 P= 0.10
Norway 428 286 477 259 0.95 0.81 -1.91 0.056 53.29 P= 0.30 P=0.045 P=0.03
Meta random 0.89 -1.19 0.235 1.47 0.23 P= 0.26 P= 0.46
rs10183087 AAD A AAD C Ctrl A Ctrl C Call rate OR Z P Q hetero P hetero Weight iAAD APS II 21-OH+ N
UK 444 158 456 172 0.955 1.06 0.45 0.651 50.91 P= 0.89 P= 0.66
Norway 594 146 595 143 0.97 0.98 − 0.17 0.864 49.09 P= 0.45 P= 0.39 P= 0.94
Meta random 1.02 0.2 0.839 0.19 0.66 P= 0.54 P= 0.83
rs1896286 AAD T AAD G Ctrl T Ctrl G Call rate OR Z P Q hetero P hetero Weight iAAD APS II 21-OH+ N
UK 372 238 382 274 0.985 1.12 1 0.319 46.82 P= 0.67 P= 0.42
Norway 445 275 444 290 0.955 1.06 0.51 0.607 53.18 P= 0.38 P= 0.96 P= 0.46
Meta random 1.09 1.06 0.29 0.14 0.71 P= 0.35 P= 0.42
Abbreviations: AAD, autoimmune Addison’s disease; APS II, autoimmune polyendocrinopathy type II; APS II, P-value for analysis of only APS II; Ctrl, control
subjects; OR, odds ratio; Z, Z-value for meta-analysis; P, P-value for the different cohorts and for the meta-analysis using the random model for calculations; Q
hetero, Q-value for heterogeneity; P hetero, P-value for heterogeneity; Weight, relative weight using the random model; iAAD, P-value for analysis of only
isolated AAD; 21-OH+ N, P-value for analysis of Norwegian patients with positive anti-21-OH autoantibodies. The distribution of alleles is given in numbers for the
cohort of patients with AAD (cases) and for control subjects (Ctrl). The call rates given in the table are the combined call rate for controls and patients. All SNPs
with a combined call rate of o95% have been rejected. Analyses have been executed by the program ‘Comprehensive meta-analysis version 2.0’ (www.meta-
analysis.com) using a random effects model. P-values which mark a signiﬁcant association (Po0.05) are marked in bold text. Norwegian cohort: Total AAD cases:
N= 382 (iAAD N= 162; APS II N= 220). Total controls: N= 380. UK cohort: Total AAD cases: N= 309 (iAAD N= 135; APS II N= 174). Total controls: N= 335.
Table 2. Meta-analysis on the effect of the CTLA-4 SNP rs231775 for AAD
Study name A AAD G AAD A Ctrls G Ctrls Odds ratio for G (95% CI) Z-value P-value Relative weight
UK Euradrenal AAD N= 309;
Ctrls N= 335
361 257 400 260 1.10 (0.88–1.37) − 0.80 0.425025 28.13
Norway Euradrenal AAD, N= 382;
Ctrls, N= 380
382 370 437 313 1.35 (1.10–1.66) − 2.90 0.003688 33.87
Brozzetti et al.3 AAD, N= 180;
Ctrls, N= 394
214 146 578 210 1.88 (1.44–2.44) − 4.69 0.000003 20.31
Donner et al.21 AAD, N= 76
Ctrls; N= 394
85 67 581 358 1.28 (0.91–1.81) − 1.39 0.163298 11.73
Perez de Nanclares et al.22 AAD, N= 57;
Ctrls, N= 111
75 39 160 62 1.34 (0.83-2.18) − 1.19 0.235072 5.96
TOTAL random modela AAD, N= 1002;
Ctrls, N= 1614
1121 885 2136 1186 1.37 (1.13–1.66) −3.15 0.002
Meta-analysis was performed using the program ‘Comprehensive meta-analysis version 2.0’ (www.meta-analysis.com), random effects model. Signiﬁcant
associations are marked with bold text in the P-value column. aBeslow-Day test of heterogeneity: P= 0.05; Hedges’s g test of heterogeneity: P= 0.05.
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for autoimmunity susceptibility in some populations, but over-
ruled by other factors in other populations.
This study also conﬁrms that the rs231775 (#9) SNP in CTLA-4 is
signiﬁcantly associated with AAD in a European meta-analysis.
Interestingly, a previous report has demonstrated that this
polymorphism exerts an effect on AAD susceptibility independent
of prevalent HLA haplotypes.3 CD28 and CTLA-4 are important for
T-cell function and signalling, and their regulation is therefore
important for maintenance of normal lymphocyte biology.
A polymorphism that diminishes CTLA-4 function or which
increases CD28 function would be predicted to result in
down-regulation of T-cell responses, favouring autoreactivity and
therefore the development of autoimmune conditions. One
important mechanism for controlling CTLA-4 and CD28 activity
is by altering their cell-surface expression.31 In 2003, Ueda et al.25
demonstrated that a 3′-UTR haplotype of CTLA-4, including the
CT60 SNP (rs30807243), was associated with altered levels of
full-length (transmembrane) and soluble (s)CTLA-4 isoforms, the
susceptibility haplotype being associated with reduced sCTLA-4
mRNA levels in man. Paradoxically, several studies have found
increased levels of sCTLA-4 in the sera of individuals with
autoimmune diseases, although newer data have challenged this
hypothesis and the effect of certain genotypes on sCTLA-4
concentration remain controversial.32–38 People over 70 years of
age have also been reported to have an increased serum level of
sCTLA-4,39 which could be a contributing factor to the high
prevalence of autoimmune diseases amongst the elderly. In
accordance with our results, the G-allele of rs231775 (#9) has been
shown to confer higher T-cell proliferation than the A-allele,
indicating a lower degree of inhibition of T-cell activity, which may
promote autoimmunity.40 However, this SNP, which is located on
the peptide leader sequence of CTLA-4, may potentially also
interfere with mRNA stability.
The impact of heterogeneity in our meta-analysis was border-
line signiﬁcant (P= 0.05). We therefore used a random effects
model which does not make the assumption that all studies
included had a uniform direction of effect. The varying inclusion
criteria between different studies and the differing frequency of
HLA haplotypes between different European subpopulations are
factors which might explain the genetic heterogeneity between
the included studies. Nevertheless, all studies included in the
meta-analysis indicate the same trend; that the G-allele of CTLA-4
SNP rs231775 (#9) contributes to AAD susceptibility.
In conclusion, this is the largest genetic study that has ever
been conducted in AAD in relation to the CTLA-4 gene and we
strengthen the evidence of an association between the CTLA-4
gene and AAD. In particular, the rs231775 (#9) polymorphism in
the CTLA-4 signal peptide is associated with AAD in the European
population, which supports a role for CTLA-4 in the pathogenesis
of AAD.
PATIENTS AND METHODS
Patient material
AAD patients were recruited from the UK (N= 309: iAAD N= 135,
autoimmune polyendocrinopathy type II (APS II) N=174) and Norway
(N= 382: iAAD N=162, APS II N= 220). For the Norwegian cohort, 290
patients (76%) were 21-OH autoantibody positive, measured by radio-
immunoassay as described elsewhere.41 In each AAD subject, the clinical
diagnosis was conﬁrmed by either a low basal cortisol with a high ACTH
level or a subnormal response to the ACTH1–24 stimulation test
(short synacthen test using 250 μg parenteral tetracosactide). Patients
1 2 3 4 5 7 8 9 10 11 13 14 15 16
Figure 2. Haploview plots of linkage disequilibrium (LD; r2) between the SNPs for the UK control cohort analysed in this study. The plot for the
Norwegian controls looked very similar. Some of the SNPs for each control cohort were excluded due to low call rate and these were not
included in the Figure. To clarify which SNPs that are included in the graph, the SNPs have also been relabelled 1–16, which corresponds to
the numbers given in Figure 1.
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with primary adrenal failure owing to inﬁltrative or infective causes or
secondary adrenal failure were excluded. In addition, patients with APS1,
on the grounds of mucocutaneous candidiasis, hypoparathyroidism and
ectodermal dystrophy, were also excluded and to our knowledge, all
included individuals were nonconsanguineous. Patients with type 1
diabetes and/or autoimmune thyroid disease in addition to AAD were
classiﬁed as having APS II. As controls, blood samples were collected from
335 and 380 healthy people from the UK and Norway, respectively. All
individuals participating in this study gave informed, written consent. The
study was approved by the Regional Ethical Committees (Leeds East in the
UK; Western Norway in Norway).
Genotyping
DNA was extracted from peripheral blood. Sixteen SNPs within the
extended CTLA-4 gene locus (encompassing CD28, CTLA-4 and ICOS) were
chosen (Figure 1). Fourteen tag-SNPs were selected from the HapMap
database, and an additional two SNPs (DIL107, promoter_1661) were
chosen for their association with the autoimmune condition systemic
lupus erythematosus.15 The DNA sequence ﬂanking each SNP was found in
the Ensembl database (~300 bp in length) and this sequence data was
then used to generate a Sequenom iPlex assay, using the MassARRAY
Designer software (Sequenom, San Diego, CA, USA). Compatibility of the
multiplex assays was checked in silico. SNPs were genotyped using the
Sequenom MassARRAY technology (Sequenom). The Iplex assay was
followed according to manufacturer’s instructions (www.sequenom.com)
using 30 ng of genomic DNA template.
Single-locus tests in Norwegian and English AAD cohorts
The UK and Norwegian cohort data were analysed separately and then
analysed in combination by meta-analysis. For each SNP a count was made
of each genotype (AA, AB and BB) in cases and controls. Genotype
frequencies were used to calculate call rates for each SNP (AA+AB+BB/
sample size × 100). Genotypes at all markers were checked for Hardy–
Weinberg Equilibrium (threshold Po0.01). SNPs with a combined call rate
(healthy controls and patients) of o95% were excluded from the analysis.
The program ‘Comprehensive meta-analysis version 2.0’ (www.meta-
analysis.com) using a random effects model was used in order to calculate
ORs, z-scores, P-values. A subgroup analysis was then performed, whereby
each cohort was divided into iAAD and APS II, (with and without 21-OH
antibodies in the Norwegian cohort only).
Haplotype analysis
Haploview42 was used to calculate nonrandom association of alleles
(linkage disequilibrium expressed as r2 in the UK and Norwegian control
cohorts (Figure 2)). The UNPHASED program43 was used to estimate
haplotype frequencies and association in the UK and Norwegian cases and
controls.
1.2.5 Meta-analysis for rs231775
‘CTLA-4’ and ‘autoimmune Addison’s disease’ were used as search terms in
Pubmed aiming to ﬁnd all studies examining this gene in AAD patients.
Studies comprising over 50 patients which investigated rs231775, and
which showed no obvious overlap with the AAD cohorts described here,
were included in the meta-analysis. The program ‘Comprehensive meta-
analysis version 2.0’ (www.meta-analysis.com) using a random effects
model was used in order to calculate ORs, z-scores and P-values. The
impact of heterogeneity in the material was calculated by Hegdes’s G’ test
and by Breslow–Day test of heterogeneity.
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